High incidence of low vitamin B12 levels in Estonian newborns.

Mol Genet Metab Rep 2018 Jun 11;15:1-5. Epub 2018 Jan 11.

Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Vitamin B12 deficiency seems to be more common worldwide than previously thought. However, only a few reports based on data from newborn screening (NBS) programs have drawn attention to that subject. In Estonia, over the past three years, we have diagnosed 14 newborns with congenital acquired vitamin B12 deficiency. Therefore, the incidence of that condition is 33.8/100,000 live births, which is considerably more than previously believed. None of the newborns had any clinical symptoms associated with vitamin B12 deficiency before the treatment, and all biochemical markers normalized after treatment, which strongly supports the presence of treatable congenital deficiency of vitamin B12. During the screening period, we began using actively ratios of some metabolites like propionylcarnitine (C3) to acetylcarnitine (C2) and C3 to palmitoylcarnitine (C16) to improve the identification of newborns with acquired vitamin B12 deficiency. In the light of the results obtained, we will continue to screen the congenital acquired vitamin B12 deficiency among our NBS program. Every child with aberrant C3, C3/C2 and C3/C16 will be thoroughly examined to exclude acquired vitamin B12 deficiency, which can easily be corrected in most cases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymgmr.2017.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772002PMC
June 2018

Publication Analysis

Top Keywords

vitamin b12
32
b12 deficiency
24
acquired vitamin
16
vitamin
8
congenital acquired
8
b12
8
deficiency
7
treatable congenital
4
congenital deficiency
4
presence treatable
4
supports presence
4
treatment supports
4
deficiency vitamin
4
b12 screening
4
actively ratios
4
began actively
4
period began
4
screening period
4
normalized treatment
4
markers normalized
4

Similar Publications